[{"data":1,"prerenderedAt":182},["ShallowReactive",2],{"drug-secukinumab":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":35,"contraindications":86,"warnings":96,"renal":104,"monitoring":105,"interactions":106,"review":107,"examples":110,"atc":111,"iran":113,"usApproval":125,"links":131,"populations":148},"secukinumab",1,{"fa":7,"en":8},"سکوکینومب","Secukinumab","antineoplastic-immunomodulating",{"fa":11,"en":12},"مهارکننده IL-17A","IL-17A inhibitor",[14],{"name":15,"market":16},"Cosentyx","US",[18,19,20],"cosentyx","کوزنتیکس","سکوکینوماب",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":30,"refs":31},"pen-150","injection","sc","150 mg\u002FmL pen or syringe (also 300 mg\u002F2 mL, 75 mg\u002F0.5 mL)",{"amount":28,"unit":29,"perVolumeMl":5},150,"mg",[16],[32],{"source":33,"section":34},"fda-cosentyx","3",[36,54,71],{"id":37,"disease":38,"label":39,"population":42,"type":46,"unit":29,"dose":47,"refs":51},"pso","psoriasis",{"fa":40,"en":41},"پسوریازیس پلاک بزرگسال — ۳۰۰ mg (هفته ۰ تا ۴، سپس هر ۴ هفته)","Adult plaque psoriasis — 300 mg (weeks 0–4, then every 4 weeks)",{"minAge":43},{"value":44,"unit":45},18,"year","notCalculated",{"reason":48},{"fa":49,"en":50},"هفته ۰، ۱، ۲، ۳ و ۴ و سپس هر ۴ هفته زیرجلدی (نه روزانه). برای برخی بیماران ۱۵۰ mg کافی است.","At weeks 0, 1, 2, 3 and 4 and then every 4 weeks SC (not daily). 150 mg may be acceptable for some patients.",[52],{"source":33,"section":53},"2.3",{"id":55,"disease":56,"label":57,"population":60,"type":46,"unit":29,"dose":62,"refs":66},"as","ankylosing-spondylitis",{"fa":58,"en":59},"اسپوندیلیت آنکیلوزان و آرتریت پسوریاتیک — ۱۵۰ mg (با یا بدون بارگذاری) هر ۴ هفته","Ankylosing spondylitis and PsA — 150 mg (with or without loading) every 4 weeks",{"minAge":61},{"value":44,"unit":45},{"reason":63},{"fa":64,"en":65},"هفته ۰، ۱، ۲، ۳ و ۴ و سپس هر ۴ هفته زیرجلدی (نه روزانه). بدون بارگذاری: ۱۵۰ mg هر ۴ هفته؛ در صورت فعال ماندن ۳۰۰ mg.","At weeks 0, 1, 2, 3 and 4 and then every 4 weeks SC (not daily). Without loading: 150 mg every 4 weeks; if still active, 300 mg.",[67,69],{"source":33,"section":68},"2.4",{"source":33,"section":70},"2.6",{"id":72,"disease":73,"label":74,"population":77,"type":46,"unit":29,"dose":79,"refs":83},"hs","hidradenitis",{"fa":75,"en":76},"هیدرادنیت چرکی بزرگسال — ۳۰۰ mg (هفته ۰ تا ۴، سپس هر ۴ هفته)","Adult hidradenitis suppurativa — 300 mg (weeks 0–4, then every 4 weeks)",{"minAge":78},{"value":44,"unit":45},{"reason":80},{"fa":81,"en":82},"هفته ۰، ۱، ۲، ۳ و ۴ و سپس هر ۴ هفته زیرجلدی (نه روزانه). پاسخ ناکافی: ۳۰۰ mg هر ۲ هفته.","At weeks 0, 1, 2, 3 and 4 and then every 4 weeks SC (not daily). Inadequate response: 300 mg every 2 weeks.",[84],{"source":33,"section":85},"2.10",[87],{"id":88,"severity":89,"text":90,"refs":93},"hyper","block",{"fa":91,"en":92},"حساسیت جدی به سکوکینومب (آنافیلاکسی، آنژیوادم).","Serious hypersensitivity to secukinumab (anaphylaxis, angioedema).",[94],{"source":33,"section":95},"4",[97],{"text":98,"refs":101},{"fa":99,"en":100},"عفونت (تست سل قبل)؛ بیماری التهابی روده (تشدید یا شروع جدید)؛ اگزمای شدید.","Infections (TB test first); inflammatory bowel disease (exacerbation or new onset); eczematous eruptions.",[102],{"source":33,"section":103},"5",[],[],[],{"status":108,"reviewer":109,"date":109},"unverified",null,[],[112],"L04AC10",{"status":114,"forms":115,"refs":120},"registered",[116],{"code":117,"en":118,"fa":119},"52257","SECUKINUMAB INJECTION, SOLUTION PARENTERAL 150 mg\u002F1mL","محلول تزریقی سکوکینومب ۱۵۰ میلی‌گرم \u002F ۱ میلی‌لیتر",[121],{"source":122,"section":123,"url":124},"darooyab-generic","G-5526\u002FSecukinumab","https:\u002F\u002Fwww.darooyab.ir\u002FG-5526\u002FSecukinumab",{"kind":126,"refs":127,"id":130},"BLA",[128],{"source":33,"section":129},"SPL approval \u002F marketing category","BLA125504",[132,135,139,143,146],{"kind":133,"url":134,"label":130},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=125504",{"kind":136,"url":137,"label":138},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=77c4b13e-7df3-42d4-81db-3d0cddb7f67a","FDA Cosentyx",{"kind":140,"url":141,"label":142},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa615011.html","Secukinumab Injection",{"kind":144,"url":145,"label":112},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L04AC10",{"kind":147,"url":124,"label":8},"darooyab",{"pregnancy":149,"lactation":158,"pediatric":166,"geriatric":174},{"level":150,"text":151,"quote":154,"refs":155},"caution",{"fa":152,"en":153},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Limited available human data with COSENTYX use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes.",[156],{"source":33,"section":157},"8.1",{"level":150,"text":159,"quote":162,"refs":163},{"fa":160,"en":161},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","There are no data on the effects of COSENTYX on the breastfed child or the effects on milk production.",[164],{"source":33,"section":165},"8.2",{"level":150,"text":167,"quote":170,"refs":171},{"fa":168,"en":169},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Subcutaneous Administration Pediatric Plaque Psoriasis The safety and effectiveness of COSENTYX have been established for the treatment of moderate to severe PsO in pediatric patients aged 6 years and older who are candidates for systemic therapy or phototherapy [see Adverse Reactions (6.1) and Clinical Studies …",[172],{"source":33,"section":173},"8.4",{"level":150,"text":175,"quote":178,"refs":179},{"fa":176,"en":177},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of the 3,430 PsO subjects exposed to subcutaneous COSENTYX in clinical trials, a total of 230 (7%) were 65 years of age and older, and 32 (1%) subjects were 75 years of age and older.",[180],{"source":33,"section":181},"8.5",1792156194966]